Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1

Shida Shangguan, Philip K. Ehrenberg, Aviva Geretz, Lauren K. Yum, Gautam Kundu, Kelly May, Slim Fourati, Krystelle Nganou‐Makamdop, LaTonya D. Williams, Sheetal Sawant, Éric Lewitus, Punnee Pitisuttithum, Sorachai Nitayaphan, Suwat Chariyalertsak, Supachai Rerks‐Ngarm, Morgane Rolland, Daniel C. Douek, Peter B. Gilbert, Georgia D. Tomaras, Nelson L. Michael, Sandhya Vasan, Rasmi ThomaseLife 2021 · DOI

TL;DR

This study identifies a specific gene expression signature that correlates with vaccine-induced protection against HIV-1. This signature is linked to antibody-dependent cellular phagocytosis (ADCP), primarily driven by monocytes, suggesting a key mechanism for vaccine efficacy and offering a potential tool for screening future vaccine candidates.

What Problem Does This Paper Address?

Developing an effective HIV vaccine has been a major challenge. While some vaccine trials have shown partial protection, the underlying mechanisms are not fully understood. Previous research identified a gene signature in non-human primates (NHPs) that correlated with protection against SIV/SHIV. This study aims to validate this signature in human trials, investigate its association with antibody-dependent cellular phagocytosis (ADCP), and pinpoint the cellular origins of this protective signature to better understand and potentially improve vaccine design.

Methods

The researchers employed several advanced techniques:

  • Bulk Transcriptomics (RNA-seq): Used to analyze gene expression in peripheral blood mononuclear cells (PBMCs) from participants in HIV vaccine trials (RV306 and HVTN 505).
  • Single-cell Transcriptomics (CITE-seq): A novel approach that simultaneously measures mRNA and cell surface protein expression from individual cells. This allowed them to identify which specific cell types were expressing the protective gene signature.
  • Gene Set Enrichment Analysis (GSEA): Used to determine if the identified gene signature was enriched in participants with specific outcomes (e.g., protection vs. infection, high vs. low ADCP).
  • Composite Gene Expression Score (GES): A computational score derived from the average standardized expression of genes within the signature, used to assess its correlation with protection and other immune responses.
  • Pathway Analysis (GeneMANIA, Metascape): To understand the biological functions and pathways associated with the genes in the protective signature.

Datasets

The study utilized data from several human and NHP HIV vaccine trials:

  • RV306 trial: An immunogenicity trial using the RV144 vaccine regimen. Data from this trial was used for transcriptomic analysis (RNA-seq and CITE-seq) and ADCP measurements.
  • HVTN 505 trial: A human efficacy trial of a DNA/rAd5 vaccine that did not show overall efficacy. This was used to test the specificity of the gene signature for protective vaccines.
  • NHP studies: Previously published data from NHP challenge studies using Ad26 and ALVAC/gp120 vaccines were used for initial validation and correlation analyses.
  • RV144 trial: Previously published microarray data was used for correlates of protection analysis.

Key Insights and Ideas

  • Specificity of the Signature: The protective gene signature was absent in a failed HIV vaccine trial (HVTN 505), strongly suggesting it's a marker of effective vaccine-induced protection, not just a general response to vaccination.
  • ADCP as a Mechanism: The study provides compelling evidence that antibody-dependent cellular phagocytosis (ADCP) is a key mechanism underlying vaccine-induced protection, mediated by the identified gene signature.
  • Monocytes are Key Players: Single-cell analysis revealed that the protective genes are predominantly expressed in myeloid cells, particularly monocytes, which are known to be crucial for ADCP.
  • GES as a Predictive Tool: The composite Gene Expression Score (GES) derived from the signature proved to be a robust correlate of reduced HIV-1 infection risk and increased vaccine efficacy, even outperforming traditional correlates like V1V2 IgG antibodies in the RV144 trial.
  • Early Detection Potential: The association of the gene signature with ADCP responses as early as 3 days post-vaccination suggests that this signature could be used to assess vaccine response early in clinical trials.

Key Results

  • The gene signature was significantly enriched in the partially protective RV144 trial and associated with decreased HIV-1 acquisition risk and increased vaccine efficacy (VE).
  • In the RV306 trial, the gene signature strongly correlated with higher magnitudes of ADCP responses.
  • CITE-seq analysis showed that genes in the signature were primarily expressed in monocytes, which are key effector cells for ADCP.
  • The GES derived from the RV144 signature was a stronger correlate of reduced HIV-1 infection risk than V1V2-specific IgG antibodies.
  • The GES was able to predict HIV-1 infection with an AUC of 0.67±0.08 and accuracy of 0.81±0.04 in the RV144 trial.

Limitations and Future Work

  • Cellular Origin Nuance: While monocytes were identified as the primary source of the signature, the authors acknowledge that the signature might represent a broader biological state rather than being strictly confined to a single cell type. Granulocytes (like neutrophils) might also play a role, but their contribution is missed in PBMC analysis.
  • Generalizability: The study emphasizes the need for replication of findings across multiple studies to strengthen the credibility of the gene signature as a correlate of protection.
  • Future Directions: The authors propose that this gene signature can serve as a valuable tool for:
  • Identifying potential mechanisms of vaccine protection (like ADCP).
  • Screening novel vaccine candidates to accelerate development.
  • Providing orthogonal insights for down-selecting vaccine candidates in human immunogenicity trials.
  • Facilitating meta-analyses of data from ongoing and past HIV vaccine trials.

Summary updated

Abstract

A gene signature was previously found to be correlated with mosaic adenovirus 26 vaccine protection in simian immunodeficiency virus and simian-human immunodeficiency virus challenge models in non-human primates. In this report, we investigated the presence of this signature as a correlate of reduced risk in human clinical trials and potential mechanisms of protection. The absence of this gene signature in the DNA/rAd5 human vaccine trial, which did not show efficacy, strengthens our hypothesis that this signature is only enriched in studies that demonstrated protection. This gene signature was enriched in the partially effective RV144 human trial that administered the ALVAC/protein vaccine, and we find that the signature associates with both decreased risk of HIV-1 acquisition and increased vaccine efficacy (VE). Total RNA-seq in a clinical trial that used the same vaccine regimen as the RV144 HIV vaccine implicated antibody-dependent cellular phagocytosis (ADCP) as a potential mechanism of vaccine protection. CITE-seq profiling of 53 surface markers and transcriptomes of 53,777 single cells from the same trial showed that genes in this signature were primarily expressed in cells belonging to the myeloid lineage, including monocytes, which are major effector cells for ADCP. The consistent association of this transcriptome signature with VE represents a tool both to identify potential mechanisms, as with ADCP here, and to screen novel approaches to accelerate the development of new vaccine candidates.
BibTeX
@inproceedings{shangguan2021monocyte,
  author = {Shida Shangguan and Philip K. Ehrenberg and Aviva Geretz and Lauren K. Yum and Gautam Kundu and Kelly May and Slim Fourati and Krystelle Nganou‐Makamdop and LaTonya D. Williams and Sheetal Sawant and Éric Lewitus and Punnee Pitisuttithum and Sorachai Nitayaphan and Suwat Chariyalertsak and Supachai Rerks‐Ngarm and Morgane Rolland and Daniel C. Douek and Peter B. Gilbert and Georgia D. Tomaras and Nelson L. Michael and Sandhya Vasan and Rasmi Thomas},
  title = {{Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1}},
  booktitle = {eLife},
  year = {2021},
  doi = {10.7554/elife.69577},
}
Figure